Search XERS
Xeris Biopharma Holdings, Inc.
Nasdaq · CIK 1867096
Last close9.08
Daily change-0.17 (-1.84%)
10 Years gain-55.09%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
XERS · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
69.2Momentum
100.0Acceleration
100.0Confidence
83.0Annual Revenue6
Quarterly Revenue18
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality21.5 / 25
Capital Efficiency9.5 / 20
Balance Sheet9.0 / 15
Shareholder Economics0.8 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 5.4112 percentage points.
Operating leverageOperating margin improved by 26.4825 percentage points.
ROIC expansionROIC improved by 30.955 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 13.367%.
Key Metrics
Revenue Growth TTM58.13%OK
Revenue CAGR 3Y38.33%OK
Gross Margin82.31%OK
Operating Margin7.57%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC12.16%OK
Incremental Operating Margin 3Y48.24%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y13.37%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $291.85M | $238.43M | $24.90M | $28.63M | n/a | 81.7% | 8.53% | n/a | 19.61% | 172.74M |
| 2025 FY Dec 31, 2024 | $203.07M | $155.40M | -$33.65M | -$36.98M | n/a | 76.52% | -16.57% | n/a | -21.92% | 146.77M |
| 2025 FY Dec 31, 2023 | $163.91M | $124.43M | -$44.01M | -$47.02M | n/a | 75.91% | -26.85% | n/a | -31.32% | 137.67M |
| 2024 FY Dec 31, 2022 | $110.25M | $76.77M | -$81.94M | -$102.89M | n/a | 69.63% | -74.32% | n/a | -67.73% | 135.63M |
| 2023 FY Dec 31, 2021 | $49.59M | $35.72M | -$115.16M | -$95.54M | n/a | 72.03% | -232.22% | n/a | -268.12% | 79.03M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $321.15M | sum latest 4 fiscal quarters Revenue | OK | 0001867096-26-000065, 0001867096-25-000159 |
| Revenue Growth TTM | 58.13% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001867096-26-000065, 0001867096-25-000159 |
| Revenue CAGR 3Y | 38.33% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001867096-26-000016 |
| Revenue CAGR 5Y | 70.67% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001867096-26-000016 |
| Gross Profit CAGR 3Y | 45.9% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001867096-26-000016 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001867096-26-000065, 0001867096-25-000159 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 82.31% | Gross Profit / Revenue | OK | 0001867096-26-000065, 0001867096-25-000159 |
| Operating Margin | 7.57% | Operating Income / Revenue | OK | 0001867096-26-000065, 0001867096-25-000159 |
| ROIC | 12.16% | NOPAT / Average Invested Capital | OK | 0001867096-26-000065, 0001867096-25-000159 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001867096-26-000065 |
| Current Ratio | 1.45x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.48x | (Cash + Short-term Investments) / Total Debt | OK | 0001867096-26-000065 |
| Revenue per Diluted Share | $1.86 | Revenue / Diluted Shares | OK | 0001867096-26-000065, 0001867096-25-000159 |